ACOG
NASDAQAlpha Cognition Inc.
Price$5.93-0.08 (-1.41%)
04:15 PM06:00 PM
News · 26 weeks62-45%
2025-12-142026-06-07
Mix3590d
- Insider12(34%)
- SEC Filings9(26%)
- Other7(20%)
- Earnings4(11%)
- Analyst2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERLarge owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- ANALYSTMaxim Group initiated coverage on Alpha Cognition with a new price targetMaxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00
- INSIDERLarge owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- INSIDERChief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $196,009 worth of shares (34,043 units at $5.76) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational UpdateZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan
- SECSEC Form 10-Q filed by Alpha Cognition Inc.10-Q - Alpha Cognition Inc. (0001655923) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- SECAmendment: Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - Alpha Cognition Inc. (0001655923) (Filer)
- SECSEC Form DEF 14A filed by Alpha Cognition Inc.DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)
- SECSEC Form DEFA14A filed by Alpha Cognition Inc.DEFA14A - Alpha Cognition Inc. (0001655923) (Filer)
- PRAlpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management
- PRAlpha Cognition Inc. to Participate in Three Upcoming Investor ConferencesAlpha Cognition, Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum's 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28,
- SECAlpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Alpha Cognition Inc. (0001655923) (Filer)
- PRAlpha Cognition Strengthens Its Board of Directors with Appointment of Bethany SensenigAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro
- INSIDERSEC Form 4 filed by Sensenig Bethany4 - Alpha Cognition Inc. (0001655923) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sensenig Bethany3 - Alpha Cognition Inc. (0001655923) (Issuer)
- ANALYSTCraig Hallum initiated coverage on Alpha Cognition with a new price targetCraig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00
- PRAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a new non-executive employee under the Company's 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the st
- SECAlpha Cognition Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Alpha Cognition Inc. (0001655923) (Filer)
- PRAlpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain InjuryAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on March 31, 2026. The patent, titled "ALPHA-1062 for treating Traumatic Brain Injury," includes claims covering methods of treating both confirmed and suspected traumatic brain injury (TBI) using ALPHA-1062. This newly issued patent strengthens Alpha Cognition's intellectual property portfolio and complements existing patents supporting both ALPHA-1062 and ZUNVEYL®. The patent provides protect
- SECSEC Form 10-K filed by Alpha Cognition Inc.10-K - Alpha Cognition Inc. (0001655923) (Filer)
- INSIDERSEC Form 4 filed by Opaleye Management Inc.4 - Alpha Cognition Inc. (0001655923) (Issuer)
ACOG FAQ
3 questionsWhere does ACOG stock trade?
Alpha Cognition Inc. (ACOG) is listed on NASDAQ.What are analysts saying about ACOG?
Alpha Cognition Inc. has had 3 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1200.00 price target on 2026-05-29. Recent price targets range from $1200.00 to $2000.00.How can I track ACOG on Quantisnow?
Quantisnow aggregates Alpha Cognition Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACOG to receive live email and push alerts on every new disclosure.